In vitro effect of ciprofibrate on human carbonic anhydrase II and glucose 6 phosphate dehydrogenase enzyme activities

Objective: Ciprofibrate (2-[4-(2,2-dichloro cyclopropyl) phenoxyl]-2-methyl propinoic acid) is a lipid-lowering drug used in the treatment of various metabolic diseases, especially hyperlipidemias. Human carbonic anhydrase II (hCA II) and glucose 6 phosphate dehydrogenase (G6PD) are crucial enzymes associated with many metabolic pathways. The aim of this study was to reveal the in vitro effect of ciprofibrate on the hydratase and esterase activities of hCAII and G6PD enzyme activity. Methods: hCA II hydratase activity was measured using the modified Wilbur-Anderson method, while esterase activity was determined using the method described by Armstrong et al. G6PD activity was determined using the Beutler method. Results: Different concentrations of ciprofibrate increased hCAII hydratase activity but exhibited no effects on hCA II esterase or G6PD activities. Conclusion: Since activation of hCA II is important in neurodegenerative diseases, such as Alzheimer’s, in which carbonic anhydrase activity decreases, the use of ciprofibrate may be proposed in the treatment of such diseases. However, this now needs to be confirmed by in vivo studies.